G. Stoter - Concepedia

Author

G. Stoter

Rotterdam University of Applied Sciences

Also Known As

Donald W. W. Newling, E.O.R.T.C. Urological Group, F.K. Engels, G J Stoter, G STOTER, G Stoter, G. STOTER, G. Stoter, Gerrit J. Stoter, Gerrit Stoter

347

Publications

16K

Citations

H-Index

150

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Cancer Institute Erasmus University Rotterdam Erasmus MC Leiden University

About

G. Stoter is an author at Rotterdam University of Applied Sciences specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	116	7.4K
2	Health Sciences	13	13	676
3	Natural Sciences	3	3	950
4	Engineering	2	2	230
5	Nursing	1	1	33

G. Stoter

178

Publications

12.9K

Citations

H-Index

Page 1

	Year	Citations
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers GM Mead, SP Stenning, Penny A. Cook, University of Groningen research database (University of Groningen / Centre for Information Technology)	1997	1K
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij, PubMed Cpt-11 BelongsChemoprevention StrategyPharmacotherapyMedicinal ChemistryPharmacological Study	2001	752
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Herman Burger, Hans van Tol, Antonius W.M. Boersma, Blood	2004	412
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists M de Boer-Dennert, Ronald de Wit, PIM Schmitz, British Journal of Cancer OncologyPatient PerceptionsPharmacologyPharmacotherapyMetronomic Chemotherapy	1997	375
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Alex Sparreboom, Lia van Zuylen, Eric Brouwer, PubMed OncologyPharmacological StudyCremophor El-mediated AlterationPaclitaxel Plasma DispositionPhysiology	1999	339
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Herman Burger, John A. Foekens, Maxime P. Look, PubMed	2003	292
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Ronald de Wit, G. Stoter, Stuart Kaye, Journal of Clinical Oncology	1997	269
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients Felix E. de Jongh, Ruben N. van Veen, S J Veltman, British Journal of Cancer	2003	265
Utility Assessment in Cancer Patients Anne M. Stiggelbout, G.M. Kiebert, J. Kievit, Medical Decision Making	1994	179
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report M. Marchand, Cornelis J.A. Punt, Steinar Aamdal, European Journal of Cancer Cancer ImmunosurveillanceMedicineImmunologyClinical ReportMage-3 Protein	2002	167

Page 1